The fund-raising values the company at $3.8 billion and underscores investor interest in using artificial intelligence to ...

Few places on the planet have more at stake in AI’s transformation and disruption of life sciences than the Massachusetts ...

With PAT, pharmaceutical manufacturers achieve real-time process control, enhancing drug quality and accelerating the ...

This article explores how new approach methodologies are transforming drug discovery through human-relevant models, including ...

Today, the integration of AI and digital technologies is fundamentally rewriting the rules of R&D—serving as the ultimate breakthrough to shatter industry bottlenecks and drive unprecedented ...

Anthropic announced the creation of its new Claude Science tool, which aims to help scientists speed up the drug development ...

The tailor-made comprehensive offering spans a diversified clinical and commercial portfolio of innovative modalities, ...

An artificial intelligence system that operates like a collaborative team of medical experts could accelerate clinical trial ...

Many clinically relevant molecules fall by the wayside because of the complex challenge of purifying them at industrial scale ...

The biotechnology company will use the federal pilot program for its planned $2 billion Saratoga Springs manufacturing campus ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

Anthropic also went a step further, saying it would develop drugs of its own. Head of life sciences Eric Kauderer-Abrams said ...